Remarkably different results between two studies from North America on genomic mutations and sensitivity to DNA demethylating agents for myelodysplastic syndromes

Remarkably different results between two studies from North America on genomic mutations and sensitivity to DNA demethylating agents for myelodysplastic syndromes

<正>Sekeres et al.(1)conducted a multicenter randomized,controlled trial to compare whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates to azacitidine in the treatment of myelodysplastic syndromes(MDS).In that trial,224 patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chinese journal of cancer research 2017-12, Vol.29 (6), p.587-588
Hauptverfasser: Wang, Guiping, Guo, Shanshan, Xiao, Huashi, Zong, Liang, Asakawa, Tetsuya, Abe, Masanobu, Hu, Wenqing, Ji, Jiafu
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:<正>Sekeres et al.(1)conducted a multicenter randomized,controlled trial to compare whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates to azacitidine in the treatment of myelodysplastic syndromes(MDS).In that trial,224 patients with higher-risk MDS and 53 with chronic myelomonocytic leukemia(CMML)were enrolled
ISSN:1000-9604
1993-0631
DOI:10.21147/j.issn.1000-9604.2017.06.14